Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients

Haemophilia

Volumn 18, Issue 2, 2012, Pages 187-192

  Epstein, J ^a   Xiong, Y ^a   Woo, P ^a   Li McLeod, J ^a   Spotts, G ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

B domain deleted; Full length FVIII; FVIII; Haemophilia; Prophylaxis; Utilization

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HEALTH INSURANCE; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; INFANT; INSURANCE, HEALTH; PEPTIDE FRAGMENTS; PHARMACEUTICAL SERVICES; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84857122984     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02636.x     Document Type: Article

References (21)

1. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
2. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). MASAC Document #179. November 4, 2007.
5. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
6. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
7. Collins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
8. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10(Suppl 1): 63-70.
9. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic versus on-demand sucrose-formulated recombinant factor viii treatment in adults with severe hemophilia a: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
10. Khair K, Lawrence K, Butler R, O'Shea E, Chrisie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008; 119: 115-23.
11. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15: 1187-96.
12. Bovenschen N, Boertjes RC, van Stempvoort G et al. Low desity lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370-7.
13. Khrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 2006; 17: 379-88.
14. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
15. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII - a robust meta-analytic finding. Haemophilia 2004; 10: 449-51.
16. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII. Haemophilia 2004; 10: 747-50.
17. Santoro C, Iorio A, Ferrante F et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779-87.
18. Di Paola J, Smith MP, Klamroth R et al. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
19. US Food and Drug Administration (FDA). Clinical pharmacology review (2/7/2008) - Xyntha. Available at Accessed August 5, 2011.
20. Rea C, Dunkerley A, Sorensen B, Rangarajan S. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. Haemophilia 2009; 15: 1237-42.
21. Zhou Z, Koerper M, Riske B et al. Healthcare utilization in persons with severe hemophilia A on prophylactic versus episodic factor replacement. Poster presented at the Annual Hemophilia & Thrombosis Research Society Sceintific Symposium, 16-18 April, 2009.